ASHM Report Back
Clinical posts from members and guests of the Australasian Society for HIV, Viral Hepatitis and Sexual Health Medicine (ASHM) from various international medical and scientific conferences on HIV, AIDS, viral hepatitis, and sexual health.
Another captivating day of presentations and lectures.
There was robust discussion regarding treatment strategies during the morning session.
Christian Callebaut from Gilead Sciences clinical virology presented on the resistance profile of treatment experienced HIV infected patients switching to elvitegravir/cobistat/emtricitabine/ tenofovir alafenamide plus darunavir. This population is known to have a high pre-existing resistance profile.
. The regimen was found to be statistically superior to staying on baseline regimen @ 48 weeks
. Treatment was simpler
. More convenient option for treatment experienced patients on complex multil pill regimens
Chloe Orkin of the Department of Infection and Immunity at the London Hospital, presented new clinical data on switching from rilpiravine/emtricitabine/tenofovir alafenamide and its safety and efficacy through 48 weeks.
. Found to be very effective
. Increased rates of viral suppression
. No emergence of resistance mutations
. Well tolerated
. Low incidence of adverse events
. Low discontinuation rates
. Improved renal and bone safety
A very full day culminated in spending time with other Australian delegates.
Busy day ahead tomorrow, starting off early with an industry symposium on helping patients stay the course.